Global Hospital Treated Gram Negative Infections Market Size By Type (Klebsiella, Acinetobacter), By Application (Hospital, Lab), By Region, And Segment Forecasts, 2023 to 2032

The Global Hospital Treated Gram Negative Infections Market was valued at USD 17.4 billion in 2023 and is expected to surpass USD 28.6 billion by 2031, growing at a CAGR of 6.5% during the forecast period from 2023 to 2031. The growth is driven by the increasing prevalence of multidrug-resistant (MDR) gram-negative pathogens, rising hospitalization rates, and the growing demand for effective antimicrobial treatments. Hospitals remain the frontline in managing severe gram-negative infections, such as pneumonia, bloodstream infections, urinary tract infections (UTIs), and intra-abdominal infections, which are increasingly resistant to first-line therapies.

Drivers:

1. Rising Antimicrobial Resistance (AMR):

The global surge in AMR, particularly among gram-negative bacteria like Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, is pushing the need for hospital-based interventions using newer antibiotics and combination therapies.

2. Increased Hospital Admissions and Surgical Procedures:

Aging populations and rising numbers of surgical interventions lead to more hospital-acquired infections, where gram-negative bacteria are often implicated, especially in intensive care units (ICUs).

3. Growing Pipeline of Novel Antibacterial Therapies:

Pharmaceutical companies are actively investing in the development of novel antibiotics, β-lactamase inhibitors, and antimicrobial peptides that target gram-negative pathogens with new mechanisms of action.

Restraints:

1. Limited Treatment Options:

Despite ongoing R&D, effective treatment options for MDR gram-negative infections remain limited. Resistance to carbapenems and colistin further complicates therapeutic strategies.

2. High Cost of Advanced Antibiotic Therapies:

The cost associated with next-generation antimicrobial treatments can be prohibitive, especially in low-resource hospital settings, limiting widespread access.

Opportunity:

1. Government and NGO Funding for AMR Research:

Global collaborations and funding initiatives such as CARB-X, GARDP, and support from the WHO are bolstering innovation in gram-negative infection treatment, presenting an opportunity for market expansion.

2. Expansion in Emerging Markets:

With rising healthcare infrastructure investment in Asia-Pacific, Latin America, and Africa, hospital-based infectious disease management is expected to grow, increasing the demand for gram-negative infection treatments.

Market by System Type Insights:

The market is segmented by drug class/system type, with β-lactam/β-lactamase inhibitors holding the largest share in 2023. These combinations remain essential due to their efficacy against a broad spectrum of gram-negative pathogens. However, polymyxins and novel tetracyclines are expected to gain traction due to their effectiveness against carbapenem-resistant strains.

Market by End-use Insights:

Tertiary care hospitals dominated the market in 2023, accounting for over 45% of global revenue, as these institutions handle complex, drug-resistant infections. Meanwhile, community hospitals are projected to grow at the fastest rate, driven by decentralization of care and improved diagnostics.

Market by Regional Insights:

North America led the global hospital treated gram-negative infections market in 2023, supported by robust healthcare infrastructure, higher incidence of MDR pathogens, and increased adoption of novel therapies. Asia-Pacific, however, is expected to experience the fastest growth due to the region’s high infection burden, rising awareness, and increased hospital capacities.

Competitive Scenario:

Key players in the market include Merck & Co., Inc., Pfizer Inc., Shionogi & Co., Ltd., Entasis Therapeutics, AbbVie Inc., AstraZeneca, Melinta Therapeutics, and Venatorx Pharmaceuticals. These companies are engaged in R&D collaborations, licensing agreements, and strategic acquisitions to enhance their antimicrobial portfolios.

Notable Developments:

2023: Shionogi launched cefiderocol in several new markets after positive clinical trial results in patients with carbapenem-resistant infections.

2024: Pfizer announced a partnership with Venatorx Pharmaceuticals to co-develop a novel β-lactam/β-lactamase inhibitor combination.

2025: Melinta Therapeutics received FDA approval for a new oral formulation targeting resistant gram-negative UTIs.

Scope of Work – Global Hospital Treated Gram Negative Infections Market

Report Metric Details

Market Size (2023) USD 17.4 billion

Projected Market Size (2031) USD 28.6 billion

CAGR (2023–2031) 6.5%

Market Segments By Drug Class (e.g., β-lactam/β-lactamase inhibitors, polymyxins), By End-use (Tertiary Hospitals, Community Hospitals), By Region

Growth Drivers Rising antimicrobial resistance, Increasing hospital-acquired infections, New drug development

Opportunities Emerging markets, Public-private partnerships, Expanded antibiotic pipelines

FAQs:

1. What is the current market size of the Global Hospital Treated Gram Negative Infections Market?

The market was valued at USD 17.4 billion in 2023.

2. What is the major growth driver of the Global Hospital Treated Gram Negative Infections Market?

The rising antimicrobial resistance and increasing hospital-acquired infections are the primary growth drivers.

3. Which is the largest region during the forecast period in the Global Hospital Treated Gram Negative Infections Market?

North America held the largest share in 2023 and is expected to retain its lead through 2031.

4. Which segment accounted for the largest market share in Global Hospital Treated Gram Negative Infections Market?

The β-lactam/β-lactamase inhibitor segment led the market in 2023.

5. Who are the key market players in the Global Hospital Treated Gram Negative Infections Market?

Key players include Merck & Co., Pfizer Inc., Shionogi & Co., Entasis Therapeutics, AstraZeneca, and Melinta Therapeutics.